A5025501697- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Rheumatoid Arthritis Research and Therapies
- Polyomavirus and related diseases
- Systemic Lupus Erythematosus Research
- Immunotherapy and Immune Responses
- Cytokine Signaling Pathways and Interactions
- Autoimmune and Inflammatory Disorders Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Neurogenesis and neuroplasticity mechanisms
- Neuroinflammation and Neurodegeneration Mechanisms
- Health Systems, Economic Evaluations, Quality of Life
- Viral Infections and Immunology Research
- SARS-CoV-2 and COVID-19 Research
- Immune Response and Inflammation
- Sphingolipid Metabolism and Signaling
- Advanced Neuroimaging Techniques and Applications
- T-cell and B-cell Immunology
- Hereditary Neurological Disorders
- Long-Term Effects of COVID-19
- Amyotrophic Lateral Sclerosis Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Systemic Sclerosis and Related Diseases
- RNA regulation and disease
- Ultrasound and Hyperthermia Applications
Icahn School of Medicine at Mount Sinai
2016-2025
Mount Sinai Medical Center
2003-2023
Allen Institute for Brain Science
2012-2023
University of Manitoba
2020-2023
Johns Hopkins University
2007-2023
The University of Texas Southwestern Medical Center
2022-2023
Karolinska Institutet
2022-2023
The University of Texas Health Science Center at Houston
2019-2022
University of Alabama at Birmingham
2007-2022
Vall d'Hebron Institut de Recerca
2022
New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis multiple sclerosis. The use imaging demonstration dissemination central nervous system lesions in space time been simplified, some circumstances can be established by a single scan. These revisions simplify Criteria, preserve their diagnostic sensitivity specificity, address applicability across populations, may allow earlier more uniform widespread use.
Abstract The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). focus remains the objective demonstration of dissemination lesions in both time and space. Magnetic resonance imaging is integrated with clinical other paraclinical methods. facilitate diagnosis patients a variety presentations, including “monosymptomatic” disease suggestive MS, typical relapsing‐remitting course, insidious progression, without clear attacks remissions....
Background: In 1996, the clinical course of multiple sclerosis (MS) was characterized as relapsing-remitting, primary progressive, secondary progressive or relapsing. Since then, an increased understanding MS and its pathology prompted a re-examination these phenotypes. Main recommendations 2013 revisions are provided herein. Summary: Clinically isolated syndrome has been added, relapsing eliminated, from descriptions. All forms should be further subcategorized either active non-active....
Standardization of terminology used to describe the pattern and course MS is essential for mutual understanding between clinicians investigators. It particularly important in design of, recruitment for, clinical trials statistically powered expected outcomes given patient populations with narrowly defined entry criteria. For agents that prove safe effective MS, knowledge definitive assists determining who may ultimately benefit from use medication. An international survey involved revealed...
Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report results two-year phase 3 trial natalizumab patients with relapsing multiple sclerosis.Of total 942 patients, 627 were randomly assigned to receive (at dose 300 mg) and 315 placebo by intravenous infusion every four weeks for more than two years. The primary end points rate clinical relapse at one year sustained progression disability, as measured Expanded Disability Status...
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment trials, treatment decision-making. Standardized published in 1996 based on a survey international MS experts provided purely phenotypes data consensus at that time, but imaging biological correlates were lacking. Increased understanding its pathology, coupled with general concern the original descriptors may not adequately reflect more...
B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ cells.
An evolving understanding of the immunopathogenesis multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody selectively depletes CD20-expressing cells, in primary progressive form disease.In this phase 3 trial, we randomly assigned 732 patients with 2:1 ratio to receive intravenous ocrelizumab (600 mg) or placebo every 24 weeks at least 120 and until prespecified number confirmed disability progression events...
Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared be safe and effective alone when added beta-1a in preliminary studies.We randomly assigned 1171 who, despite had at least one relapse during 12-month period before randomization receive continued combination with 300 mg natalizumab (589 patients) or placebo (582 intravenously every 4 weeks for up 116 weeks....
Overview.Clinical types of MS.MS is a chronic recurrent inflammatory disorder the CNS.2][3][4][5] The symptoms MS vary, depending in part on location plaques within CNS.Common include sensory disturbances limbs, optic nerve dysfunction, pyramidal tract bladder or bowel sexual ataxia, and diplopia. 5our different clinical courses have been defined. 6The first, relapsing-remitting (RRMS), characterized by self-limited attacks neurologic dysfunction.These develop acutely, evolving over days to...
Abstract Because of the major difficulties in measuring clinical end points multiple sclerosis (MS) treatment trials, there has been much enthusiasm for using magnetic resonance imaging (MRI) findings as an alternative outcome. To provide international consensus guidelines use MRI MS a task force US National Society was convened. The recommendations are presented this review. Given high sensitivity detecting pathological activity relapsing‐remitting and secondary progressive MS, monthly...
To determine the percentage of patients with residual deficits following multiple sclerosis (MS) exacerbations and magnitude those using a database pooled placebo from clinical trials.A assigned to group in several randomized trials was queried Expanded Disability Status Scale (EDSS) Scripps Neurologic Rating assessments prior to, at time of, after an acute exacerbation MS. The extent deficit present these points compared effect degree persistent disability.Forty-two percent had least 0.5...
In a 2-year, placebo-controlled trial (the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis [AFFIRM] study), involving 942 patients with relapsing multiple sclerosis (MS), natalizumab significantly reduced the relapse rate by 68% progression of sustained disability 42% vs placebo. We report effect on MRI measures from AFFIRM study.The number volume gadolinium (Gd)-enhancing, new or enlarging T2-hyperintense, T1-hypointense lesions brain parenchymal fraction were...
<b>Objective: </b> To determine the incidence and clinical effects of antibodies that develop during treatment with natalizumab. <b>Methods: In two randomized, double-blind, placebo-controlled studies (natalizumab safety efficacy in relapsing remitting multiple sclerosis [MS, AFFIRM] natalizumab combination interferon β-1a [INFβ1a] patients MS [SENTINEL]) sclerosis, blood samples were obtained at baseline every 12 weeks to presence against Antibodies measured using an ELISA. Patients...
Patients with multiple sclerosis acquire disability either through relapse-associated worsening (RAW) or progression independent of relapse activity (PIRA). This study addresses the relative contribution relapses to over course disease, how early begins and extent which therapies delay accumulation. Using Novartis-Oxford (NO.MS) data pool spanning all phenotypes paediatric sclerosis, we evaluated ∼200 000 Expanded Disability Status Scale (EDSS) transitions from >27 patients ≤15 years...
<h3>Background:</h3> Due to a heightened risk of progressive multifocal leukoencephalopathy (PML) with increased natalizumab exposure, some physicians interrupt treatment patients multiple sclerosis (MS) despite lack data regarding the safety interruption, rate and severity MS disease activity return after or alternative strategies. <h3>Objectives:</h3> To determine effects interruption on clinical MRI measures in relapsing MS. <h3>Methods:</h3> Clinical relapses gadolinium-enhanced (Gd+)...
To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis (OPTIMUM) trial is first phase 3 study comparing 2 oral disease-modifying therapies for relapsing multiple sclerosis (RMS).